Intrahepatic Cholestasis of Pregnancy
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Intrahepatic cholestasis typically causes itching without a primary rash. Fetal risk assessment depends on bile-acid concentration and other pregnancy risks, rather than the intensity of itch alone.
Assessment & interpretation
- Check liver function and bile acids and examine for another cause of itch. Persistent symptoms can precede abnormal blood results, so repeat testing may be needed.
- Review gestation, multiple pregnancy, diabetes, pre-eclampsia and other factors that affect the birth plan.
Decisions that change management
- Discuss symptom relief separately from prevention of fetal complications. Ursodeoxycholic acid may modestly reduce itch but does not prevent stillbirth.
- Agree timing of birth with the obstetric team using the peak bile-acid level, gestational age and additional risk factors.
Follow-up & safety-netting
- Arrange repeat blood tests and an individual monitoring plan. Advise prompt assessment for reduced fetal movements.
- At the postnatal review, confirm that itching and biochemical abnormalities have resolved; persistent abnormalities need further investigation.
- Discuss recurrence and checking liver tests and bile acids early in a subsequent pregnancy.
Clinical pitfalls
- A symptom-improvement response should not be interpreted as proof that fetal risk has disappeared.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Admit maternal/fetal compromise, severe alternative liver disease concerns, significant bleeding/coagulopathy or another obstetric indication; assess reduced movements immediately.
When clinic, day care or home care may be suitable
- Stable ICP is commonly monitored outside hospital with symptom, bile-acid and liver-test review and a documented birth plan.
Before going home
- The diagnosis and alternative causes have been assessed; results, repeat testing and timing/place of birth are documented.
- After birth, explain expected resolution and the need to confirm it rather than assuming persistent itching or abnormal tests are normal.
Discharge medicines and treatment changes
- Continue only symptom treatment that has been prescribed; UDCA does not replace the birth/surveillance plan. Routine vitamin K is not required for every patient.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
Only when prescribed for maternal symptoms; review continuation after birth.
- Indication: Maternal itching in confirmed intrahepatic cholestasis; not a substitute for bile-acid-based birth planning
- SMFM/ACOG-endorsed guidance supplies the dose. RCOG counselling: symptom benefit is limited and UDCA does not prevent stillbirth.
- Itch, bile acids/LFTs and treatment tolerance; repeat postnatal liver tests/bile acids at about 6 weeks
Tests, pending results and their reviewer
- Arrange repeat bile acids/LFTs according to the clinical plan; at the 6-week postnatal check confirm symptoms and blood tests have resolved, with further assessment if not.
Home care and counselling
- Provide the fetal-movement and urgent-contact plan and explain how bile-acid results affect birth timing.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
At each arranged blood-test/obstetric review | Review the current result and birth plan rather than relying on an old peak alone. |
6 weeks after birth | Check symptom resolution and liver/bile-acid results; refer persistent abnormalities. |
Return urgently
- Reduced movements, jaundice, bleeding, severe upper abdominal pain, fever or systemic illness requires prompt assessment.
Open the complete discharge checklist →
Treatment
① Immediate stabilization — first minutes
Not acute unless fetal compromise.
③ First-line treatment & drug regimens
- Maternal itching in confirmed intrahepatic cholestasis; not a substitute for bile-acid-based birth planning
- SMFM/ACOG-endorsed guidance supplies the dose. RCOG counselling: symptom benefit is limited and UDCA does not prevent stillbirth.
- Itch, bile acids/LFTs and treatment tolerance; repeat postnatal liver tests/bile acids at about 6 weeks
Most patients with ICP do not need vitamin K. Check PT/INR if clinically indicated, assess malabsorption and obtain a specific haematology/pharmacy prescription if deficiency/coagulopathy is present. Menadiol and phytomenadione are different products; the old routine “vitamin K 10 mg” instruction was insufficient and could select a product contraindicated in late pregnancy.
Guideline conflict
NHS Lanarkshire local ICP pathway, October 2020
Discusses off-label menadiol 10 mg daily from 34 weeks, particularly with prolonged PT, and acknowledges neonatal risks.
Menadiol 10 mg product information / current RCOG counselling
The product contraindicates use in late pregnancy because of neonatal haemolysis, hyperbilirubinaemia and kernicterus risk. RCOG says most women with ICP do not need vitamin K.
Population/setting difference: The older local pathway proposes off-label use in the very pregnancy stage covered by the product contraindication; the disagreement is not resolved by calling every preparation “vitamin K”.
Practical India consideration: Confirm the exact vitamin K molecule, formulation and indication with obstetric/haematology/pharmacy review; do not substitute menadiol for phytomenadione.
Reason: This avoids applying an older local proposal despite a clear product contraindication and avoids treating women without a demonstrated need.
Definitive treatment
Birth resolves; LFTs/bile acids normalize within weeks postpartum.
Monitoring
- Weekly bile acids/LFTs
- CTG/growth surveillance per unit policy (esp. severe band)
Response assessment
- Itch improvement (UDCA); stable labs
Treatment failure
- Escalating acids -> expedite birth decision
Second-line treatment
- Rifampicin adjunct (rare, specialist)
Rescue treatment
Coagulopathy near birth: vitamin K IV + FFP availability.
Procedure / surgery
Induction reasonable; continuous CTG in labour common practice.
Escalation
- Hepatology if jaundice severe/atypical features
⑮ Complications & their management
Stillbirth (band-related)
Timed-birth strategy mitigates; document reasoning
Postpartum persistence
Recheck LFTs 6 wks; investigate chronic liver disease if abnormal
Post-treatment care
- LFT normalization confirmation
- Recurrence 60-90% next pregnancies - early bile-acid plan
- Avoid oestrogen-containing contraception until resolved
Diagnosis & assessment
- Bile acids >=100 µmol/L (highest stillbirth band)
- Jaundice
- Abnormal CTG
- Steatorrhoea/vitamin-K deficiency signs
Definition: Impaired bile flow in late pregnancy: pruritus + fasting serum bile acids >19 µmol/L (or ALT/AST rise) resolving postpartum.
Initial assessment
- Fasting serum bile acids + LFTs
- Exclude other causes: viral hepatitis serology, gallstones US, PET overlap labs
Investigations
| Test | Looking for |
|---|---|
Bile acids (fasting) | Severity stratification axis |
ALT/AST + GGT | Pattern support |
Principles & follow-up
Management principles
Sources (10)
2011 (reviewed; listed current on index 2026-08) · checked 2026-08-23 · pending-verification
Open source ↗
Presence on current RCOG index only — FULL TEXT AUDIT REQUIRED before relying on thresholds (marked in-app)
· checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for icp. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/discharge check 18 Oct…
· checked 2026-10-17 · verified-live
Open source ↗
Contraindication in mothers in pre/postnatal periods and late pregnancy; neonatal haemolytic anaemia, hyperbilirubinaemia/kernicterus warning. Used to flag a conflict with an older local obstetric-cholestasis pathway, not to recommend this drug routinely.
· checked 2026-10-17 · verified-summary
Open source ↗
Older local pathway proposes off-label menadiol 10 mg/day from 34 weeks, discusses prolonged PT and neonatal risks. Its age and conflict with the product contraindication are displayed; it is not the app default.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary PDF: UDCA starts 10–15 mg/kg/day in two/three doses, titration to at most 21 mg/kg/day for symptoms. Birth timing and fetal-risk counselling are distinct from symptom treatment; RCOG patient guidance separately confirms no demonstrated stillbirth prevention. Additional admission/dischar…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.